Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Haverkate

Showing results (41-50 of 73) with videos related to

Pageof 8
Sort By:
Thrombosis and Haemostasis|June 3, 1987
Fibrinogens "Milano II"- and "Naples"F Haverkate, J Koopman, C Kluft, et al.
Lancet (London, England)|February 15, 1997
Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study GroupF Haverkate, S G Thompson, S D Pyke, et al.
Thrombosis and Haemostasis|June 1, 1997
Normal prevalence of factor V Leiden gene mutation in patients with severe unstable anginaP W Verheggen, B T Heymans, P E Slagboom, et al.
Thrombosis and Haemostasis|April 7, 1987
Influence of factor XIIIa activity on human whole blood clot lysis in vitroJ W Jansen, F Haverkate, J Koopman, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 1, 1993
The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrinP Grailhe, C Boyer-Neumann, F Haverkate, et al.
The New England Journal of Medicine|March 9, 1995
Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study GroupS G Thompson, J Kienast, S D Pyke, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 15, 1992
Abnormal fibrinogens IJmuiden (B beta Arg14----Cys) and Nijmegen (B beta Arg44----Cys) form disulfide-linked fibrinogen-albumin complexesJ Koopman, F Haverkate, J Grimbergen, et al.
The Journal of Laboratory and Clinical Medicine|January 1, 1987
New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibodyJ Koopman, F Haverkate, P Koppert, et al.
Circulation|November 1, 1996
Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and DisabilitiesI Juhan-Vague, S D Pyke, M C Alessi, et al.
Thrombosis and Haemostasis|April 7, 1987
The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cellsN J de Fouw, V W van Hinsbergh, Y F de Jong, et al.
Pageof 8

Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Thrombosis and Haemostasis|June 3, 1987
Fibrinogens "Milano II"- and "Naples"F Haverkate, J Koopman, C Kluft, et al.
Lancet (London, England)|February 15, 1997
Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study GroupF Haverkate, S G Thompson, S D Pyke, et al.
Thrombosis and Haemostasis|June 1, 1997
Normal prevalence of factor V Leiden gene mutation in patients with severe unstable anginaP W Verheggen, B T Heymans, P E Slagboom, et al.
Thrombosis and Haemostasis|April 7, 1987
Influence of factor XIIIa activity on human whole blood clot lysis in vitroJ W Jansen, F Haverkate, J Koopman, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 1, 1993
The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrinP Grailhe, C Boyer-Neumann, F Haverkate, et al.
The New England Journal of Medicine|March 9, 1995
Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study GroupS G Thompson, J Kienast, S D Pyke, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 15, 1992
Abnormal fibrinogens IJmuiden (B beta Arg14----Cys) and Nijmegen (B beta Arg44----Cys) form disulfide-linked fibrinogen-albumin complexesJ Koopman, F Haverkate, J Grimbergen, et al.
The Journal of Laboratory and Clinical Medicine|January 1, 1987
New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibodyJ Koopman, F Haverkate, P Koppert, et al.
Circulation|November 1, 1996
Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and DisabilitiesI Juhan-Vague, S D Pyke, M C Alessi, et al.
Thrombosis and Haemostasis|April 7, 1987
The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cellsN J de Fouw, V W van Hinsbergh, Y F de Jong, et al.
Pageof 8